Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • PR Newswire Amplify™
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Sign Up
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media Enquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR

Sun Pharma Canada Launches (PR)ABSORICA LD® (isotretinoin capsules) for Treatment of Severe Acne Français

Sun Pharma Canada Inc. Logo (CNW Group/Sun Pharma Canada Inc.)

News provided by

Sun Pharma Canada Inc.

Dec 04, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

  • ABSORICA LD, a new micronized formulation of isotretinoin is now available in Canada for patients 12 years of age and older.
  • The only micronized formulation of isotretinoin that provides enhanced bioavailability, resulting in comparable rate and extent of isotretinoin exposure with or without food.

BRAMPTON, ON, Dec. 4, 2023 /CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomb: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma") today announces that PRABSORICA LD (isotretinoin capsules) is now available in Canada.

ABSORICA LD is a new formulation of isotretinoin, the first in over a decade, and the only micronized formulation of isotretinoin molecule which is used to treat severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne in patients 12 years of age and older.1, 2, 3, 4

Continue Reading
ABSORICA LD Product (CNW Group/Sun Pharma Canada Inc.)
ABSORICA LD Product (CNW Group/Sun Pharma Canada Inc.)

"This solution opens doors for Canadians that have been searching for a new micronized solution to treat their severe acne," said Dr. Davindra Singh, founder and lead dermatologist of AvantDerm. "Knowing the impact that severe acne has on the lives of patients, I look forward to seeing the potential results from this new treatment option." 

Severe acne causes breakouts that often extend deep into the skin, including cysts and nodules that disfigure the face. These breakouts tend to be painful, and negatively impact a patient's quality of life. Even as severe acne clears, acne scars and pigmentation often appear.5

"ABSORICA LD brings a novel, micronized formulation of isotretinoin to deal with severe nodular acne to Canadians," said Abhay Gandhi, North America CEO of Sun Pharma. "This launch is an important addition to Sun Pharma's portfolio of acne products and reflects our commitment to providing innovative dermatology medicines that address Canadian patients' needs."

ABSORICA LD is the only micronized formulation of isotretinoin, providing enhanced bioavailability that results in comparable rate and extent of isotretinoin exposure with or without food.6

For more information about ABSORICA LD, ask your physician, visit www.sunpharma.com/canada or call 1-833-388-0532.

About PRABSORICA LD (isotretinoin capsules)

ABSORICA LD is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne in patients 12 years of age and older, and is taken orally with or without food, as whole capsules either as a single dose or in two divided doses, as instructed by a physician.6   Because of significant adverse reactions associated with its use, ABSORICA LD is reserved for patients with severe acne who are unresponsive to standard therapy, including systemic antibiotics.

Capsules come in 8 mg, 16 mg, 24 mg and 32 mg strengths. Each box comes with 30 capsules as three blister packs of 10 capsules each.

Sun Pharma is committed to distributing important safety information about ABSORICA LD through its Clinical Awareness Resource and Education C-A-R-ETM Program. More information can be found here www.absoricald.ca.

About Sun Pharma Canada Inc.

Sun Pharmaceutical Industries Limited is growing its presence in Canada, bringing together the power of a global network with localized research and care to address the unmet needs of Canadian patients and healthcare providers.

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, is focused on providing innovative medicines in dermatology and ophthalmology, bringing greater access and support for patients.

Patients and healthcare providers are at the centre of everything and Sun Pharma's "passion is clear". Sun Pharma's commitment to listening, acting and caring means the team is able to respond to distinct needs and provide personalized care, while addressing important gaps in treatment and quality of life.

Sun Pharma offers a wide range of affordable medicines for the Canadian population. Together with Taro Pharmaceutical Industries Ltd. (a subsidiary of Sun Pharma) these complementary companies bring together capabilities in specialty and niche segments coupled with a presence in the top 15 Canadian generic products.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live.

References:

  1. (2023, January 24). Search Results for Isotretinoin [Review of Search Results for Isotretinoin]. Health Canada - Drug Product Database. https://health-products.canada.ca/dpd-bdpp/dispatch-repartition
  2. Health Canada. (2010). Product Information - CLARUS (Drug Product Database, Ed.) [Review of Product Information - CLARUS]. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74320
  3. Health Canada. (2013). Product Information - EPURIS (Drug Product Database, Ed.) [Review of Product Information - EPURIS]. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88199
  4. Health Canada. (2001). Product Information – Accutane Roche (Drug Product Database, Ed.) [Review of Product Information – Accutane Roche]. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5129
  5. (n.d.). WHAT CAN CLEAR SEVERE ACNE? American Academy of Dermatology Association. Retrieved May 18, 2023, from https://www.aad.org/public/diseases/acne/derm-treat/severe-acne#:~:text=Severe%20acne%20causes%20breakouts%20that,how%20stubborn%20it%20can%20be.
  6. PRABSORICA LD® (Isotretinoin Capsules) Product Monograph Including Patient Medication Information. Sun Pharmaceutical Industries Limited.; June 22, 2023

SOURCE Sun Pharma Canada Inc.

Dr. Abhishek Sharma, Tel +91 22 4324 4324, Xtn 2929 Tel Direct +91 22 4324 2929, E-mail [email protected]; Media: Gaurav Chugh, Tel +91 22 4324 4324, Xtn 5373, Tel Direct +91 22 4324 5373, Mobile +91 98104 71414, E-mail [email protected]; Canadian Media: Janet Metz, Mobile +1 609-389-3044, E-mail [email protected]

Modal title

Organization Profile

Sun Pharma Canada Inc.

    Also from this source

  • ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis

  • Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Platform Login
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.